EXAS: The acquisition of Exact Sciences Corporation (EXAS) by Abbott Laboratories (ABT) for a closing value of $23 billion. Abbott will acquire all outstanding shares of Exact Sciences for $105 per common share in cash, representing a premium of 21.84% from the stock’s last close. (Press Release)
You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.
Only plus or premium subscribers can access this post. Subscribe today.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
